TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Open Orphan Plc ( (GB:HVO) ) has provided an announcement.
hVIVO plc’s German subsidiary, CRS, has secured over £5 million in early-phase clinical trial service contracts with five clients, including two returning mid-sized German pharma companies. These contracts, which will commence in 2025 and 2026, will enhance the company’s sales pipeline and orderbook, with trials focusing on multiple therapeutic areas such as cardiometabolic and cancer. The integration of CRS into hVIVO has resulted in cross-selling benefits and improved operational efficiency, positioning CRS to become earnings accretive by 2026, thereby strengthening hVIVO’s market position in early-phase clinical research.
The most recent analyst rating on (GB:HVO) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Neutral.
Open Orphan Plc’s stock score is primarily driven by its strong financial performance and attractive valuation. However, the weak technical indicators suggest caution. The company’s low P/E ratio and solid dividend yield are significant positives, but bearish market momentum and oversold conditions highlight potential risks.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a wide range of clients, including major biopharma companies. It operates state-of-the-art facilities in London and through its German subsidiary, CRS, offers early-phase clinical trial services in Mannheim and Kiel. Additionally, its subsidiary Venn Life Sciences provides consulting and biometry services, enhancing its drug development solutions from preclinical stages through Phase II trials.
Average Trading Volume: 2,088,133
Technical Sentiment Signal: Sell
Current Market Cap: £43.28M
For an in-depth examination of HVO stock, go to TipRanks’ Overview page.